Inhibikase Therapeutics, Inc. (NYSE:IKT - Get Free Report) shares rose 4.9% during trading on Monday . The stock traded as high as $2.40 and last traded at $2.36. Approximately 175,997 shares were traded during trading, a decline of 20% from the average daily volume of 220,970 shares. The stock had previously closed at $2.25.
Analysts Set New Price Targets
Separately, HC Wainwright downgraded Inhibikase Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 12th.
Read Our Latest Report on Inhibikase Therapeutics
Inhibikase Therapeutics Stock Performance
The firm's 50 day simple moving average is $2.47 and its 200 day simple moving average is $2.34. The firm has a market capitalization of $165.08 million, a price-to-earnings ratio of -0.90 and a beta of 1.04.
Institutional Trading of Inhibikase Therapeutics
A number of hedge funds have recently added to or reduced their stakes in IKT. Soleus Capital Management L.P. acquired a new stake in shares of Inhibikase Therapeutics during the 4th quarter valued at about $20,556,000. Fairmount Funds Management LLC purchased a new position in shares of Inhibikase Therapeutics during the 4th quarter valued at approximately $19,906,000. ADAR1 Capital Management LLC purchased a new stake in Inhibikase Therapeutics in the 4th quarter worth $16,585,000. Nantahala Capital Management LLC acquired a new position in Inhibikase Therapeutics during the fourth quarter worth $7,118,000. Finally, Blackstone Inc. purchased a new position in Inhibikase Therapeutics during the fourth quarter valued at $6,730,000. 3.81% of the stock is owned by hedge funds and other institutional investors.
Inhibikase Therapeutics Company Profile
(
Get Free Report)
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
Further Reading
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
